(AOF) – Abionyx Pharma announces that it is the beneficiary of innovation aid of nearly 1 million euros from Bpifrance. The biotech specialist in innovative therapies based on the only natural recombinant apoA-I in the world specifies that this aid is intended to support the drug candidate CER-001 dedicated to the treatment of a severe indication in ophthalmology. This aid will be repayable at 0 rate on condition of success from the last quarter of 2026 until the first quarter of 2031.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.